Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-lin
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy f
| Condition(s) | Gastric Cancer Adenocarcinoma Metastatic |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients. |
| Who can participate | Inclusion Criteria: 1. Patients with histopathological confirmed gastric/GEJ adenocarcinoma. 2. The clinical stage was IV, according to AJCC 8th edition. 3. Patients had received at least two systematic therapies. 4. Patients had received or not received immunotherapy. 5. The patients received or did not receive anti-VEFGR targeted therapy in the last treatment (e.g., Bevacizumab, Ramucirumab, anti-VEGFR TKIs, etc.). 6. Age ≥18. 7. ECOG physical status score is 0-2 without deterioration within 2 weeks before the first administration of the investigational drug. 8. Adequate organ function according to the following laboratory test values: 1. Hemoglobin value ≥90g/L. 2. White blood cell count ≥3.5\*109/L. 3. Absolute neutrophil count ≥1.5\*109/L. 4. Platelet count ≥100\*109/L. 5. Serum creat |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | LIN YANG |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2024-11-14 |
| NCT ID | NCT06711471 |
| Official listing | https://clinicaltrials.gov/study/NCT06711471 |